Education and Training
- Resident, Medicine, Stanford University School of Medicine, 1990 - 1991
- Intern, Medicine, Stanford University School of Medicine, 1989 - 1990
- M.D., Stanford University, 1989
Suarez-Cuervo, C., N. L. Bryant, R. D. Lopez, G. Y. Gillespie, and L. S. Lamb. “Ex vivo activation and expansion of γδ T cells for immunotherapy of glioblastoma..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).
Gehrs, B. C., and R. D. Lopez. “Ex vivo expansion of gamma delta-T lymphocytes from melanoma patients and healthy control donors.” In Transfusion, 45:8A-8A. BLACKWELL PUBLISHING, 2005.
Liu, Zhiyong, Ben L. Guo, Bradley C. Gehrs, Li Nan, and Richard D. Lopez. “Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro..” J Urol 173, no. 5 (May 2005): 1552–56. https://doi.org/10.1097/01.ju.0000154355.45816.0b.
Guo, Ben L., Klaus A. Hollmig, and Richard D. Lopez. “Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12..” Cancer Immunol Immunother 50, no. 11 (January 2002): 625–37. https://doi.org/10.1007/s00262-001-0244-4.
Vaughan, W. P., R. O. Katz, D. E. Salzman, A. B. Tilden, R. D. Lopez, A. Garcia, O. Pena, M. Shackelford, and M. H. Carabasi. “MRD allo transplantation using a large volume leukopheresis product mobilized with G-CSF and Decadron, pharmacokinetics directed modest dose intravenous busulfan plus fludarabine conditioning, and long MTX/CSA results in sustained engraftment, low 30 day mortality, and low incidence of severe GVHD..” Blood 98, no. 11 (November 16, 2001): 200A-200A.
Lopez, R. D., E. K. Waller, P. H. Lu, and R. S. Negrin. “CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells..” Cancer Immunol Immunother 49, no. 12 (February 2001): 629–40.
Lopez, R. D., E. K. Waller, P. H. Lu, and R. S. Negrin. “CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells.” Cancer Immunology, Immunotherapy 49, no. 11 (December 1, 2000): 629–40.